QUICK ANSWER
Coverage Overview
Short answer: Increasingly, yes. Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize), including standard Aetna commercial formularies, as an "additional preferred option" for plans that cover weight-loss drugs.[14] From July 1, 2025 to September 30, 2026, Zepbound was nonpreferred or excluded on CVS Caremark's most common commercial template formularies, including standard Aetna formularies. Employers and plans can customize their formulary, so some may still exclude it — formulary exception requests remain an option there.
Is Zepbound covered by Aetna?
Coverage depends on your plan type and employer decisions:
- Since October 1, 2026: Zepbound is an additional preferred option again on CVS Caremark's commercial template formularies; if your plan covers weight-loss drugs, prior authorization still applies[15]
- July 1, 2025 – September 30, 2026: Zepbound was excluded on Aetna's standard template formularies (such as Standard and Advanced Control), though not on every plan[2]
- Employers and plans can customize their formulary—check whether yours still excludes Zepbound
- CVS's Oct 1 announcement didn't address the sleep-apnea (OSA) use; Aetna's published Zepbound criteria include an OSA route[15]
Who this guide is for
Aetna members exploring Zepbound coverage through employer-sponsored commercial plans or Aetna Medicare Advantage. (Aetna stopped selling ACA marketplace (individual exchange) plans for 2026.)
Why Coverage Varies by Plan Type
Whether Aetna covers Zepbound depends on who controls your benefits and your plan type. This is why two Aetna members can receive completely different coverage decisions.
- CVS Caremark (Aetna's PBM) made Zepbound nonpreferred or excluded on its most common commercial template formularies from July 1, 2025 to September 30, 2026, and added it back to its commercial template formularies as an additional preferred option on October 1, 2026[1][14]
- Employers (especially self-funded ones) can customize the formulary, so some plans may still exclude Zepbound or weight-loss drugs
- Formulary exception requests are still possible with strong medical documentation
To determine your exact coverage, check directly with Aetna. If you're denied, you still have options.
What to Know If You're Denied
Independent analyses show that 65%+ of appealed denials are overturned when properly documented[5]—yet only about 1 in 10 patients ever appeal.[8] Whether you've already been denied or are preparing for prior authorization, you still have options.
Denied already? See your appeal options →
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get starteddenied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
"I found Honest Care online and was very impressed with the letter... the appeal worked!"
"My Appeal was approved the next day. Thank you Honest Care!"
Coverage Outlook for 2026
Aetna's Zepbound exclusion ended on standard (template) formularies: Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize). Customized employer formularies may still exclude it, and CVS's announcement didn't address OSA. For Medicare, the GLP-1 Bridge is live (July 1, 2026 – December 31, 2027).
Read Honest Care’s GLP-1 Patient Access Report (2025) →
Last updated October 6, 2026 · Key facts verified October 5, 2026 · Full page reviewed October 5, 2026
Aetna's Key Coverage Factor: CVS Caremark
Unlike insurers with regional variation, Aetna coverage is primarily controlled by one factor: CVS Caremark, their pharmacy benefit manager (PBM).
Aetna coverage depends on two things:
- Your Plan Type — self-funded employer / standard commercial / Medicare / Medicaid
- CVS Caremark Formulary — the PBM whose most common commercial template formularies made Zepbound nonpreferred or excluded in July 2025, and which added it back as a preferred option on October 1, 2026
Self-funded employer plans can customize CVS Caremark's formulary, including whether weight-loss drugs are covered at all. Check your plan type →
Pro tip: Ask HR if your plan is "self-funded" — if so, your employer decides coverage, not Aetna.
Things to Keep in Mind
- CVS Caremark's template-formulary exclusion has ended — Zepbound was nonpreferred or excluded on CVS Caremark's most common commercial template formularies July 1, 2025 – September 30, 2026, and has been an additional preferred option on its commercial template formularies since October 1, 2026[14]
- Employers can customize — check with HR whether your plan covers weight-loss drugs and still lists Zepbound
- If denied, file an appeal — 65%+ of appealed denials are overturned when properly documented.[5]
- Other insurers may cover OSA — for example, UnitedHealthcare has a Zepbound-only commercial sleep-apnea policy[10]
If this feels overwhelming, you're not alone. The sections below walk through how to check your actual coverage before you fill the prescription.
But the default formulary isn't the full story. Your plan type can matter just as much, and employers can customize coverage, including excluding weight-loss drugs.
See how CVS Caremark affects your coverage →WHY AETNA RESTRICTED ZEPBOUNDThe CVS Caremark Connection
The CVS Caremark Connection
Understanding why Aetna's standard formularies restricted Zepbound from July 2025 to September 2026 helps explain your options.
CVS Health Owns Both Aetna and CVS Caremark
CVS Health acquired Aetna in 2018, and CVS Caremark is the pharmacy benefit manager for Aetna's standard commercial plans (some employer plans may use a different PBM). When CVS Caremark made Zepbound nonpreferred or excluded on its most common commercial template formularies on July 1, 2025, Aetna's standard formularies followed; on October 1, 2026, CVS Caremark added Zepbound back to its commercial template formularies as an additional preferred option.[1][2][14]
Why CVS Caremark Dropped Zepbound
- Better pricing from Novo Nordisk: CVS Caremark said it partnered with Novo Nordisk to offer Wegovy "at a more affordable price," making Wegovy its preferred option[1]
- Cost control: GLP-1 medications are expensive (list price about $1,086/month for Zepbound), and PBMs manage costs by limiting options
- Exclusivity agreements: Drug manufacturers compete for preferred formulary status by offering rebates
What This Means for Aetna Members
- Standard Aetna plans: Zepbound excluded July 1, 2025 – September 30, 2026 (Wegovy preferred); since October 1, 2026, Zepbound and Wegovy are both preferred
- Self-funded employer plans: Can choose whether to cover weight-loss drugs and which ones
- Other drugs in Aetna's weight-loss criteria: Wegovy, Saxenda and Foundayo (where your plan covers weight-loss drugs)[15]
For more details on how CVS Caremark affects GLP-1 coverage across all insurers: Complete CVS Caremark Guide →
Now that you understand the CVS Caremark connection, your plan type determines whether you can override it.
See how plan type affects coverage →PLAN TYPE DETERMINES YOUR OPTIONSHow Plan Type Affects Coverage
How Plan Type Affects Coverage
Your Aetna Zepbound coverage is shaped by two things working together:
- Your Plan Type — who controls your benefits (your employer vs Aetna)
- CVS Caremark Formulary — the default drug list (its most common commercial template formularies made Zepbound nonpreferred or excluded from July 2025 to September 2026)
These two things combine to create your actual coverage situation.
Think of it this way:
CVS Caremark's formulary is the "default setting" — but self-funded employer plans can change those defaults.
That's why two people with Aetna — at different employers — can get completely different answers.
Aetna Plan Types and Coverage Status
| Your Plan Type | Coverage Status | Key Details |
|---|---|---|
| Standard Plan | Preferred again (10/1/26) | CVS Caremark formulary applies; excluded 7/1/25–9/30/26, now preferred alongside Wegovy; PA applies[14] |
| Advanced Control Plan | Preferred again (10/1/26) | Same template formulary change; check whether your plan customized it[14] |
| Self-Funded Employer | Varies | Employers can customize; check with HR (see tips below) |
| ACA Marketplace | Not sold in 2026 | Aetna stopped selling ACA marketplace (individual exchange) plans for 2026 |
| Medicare Advantage | Not by the plan; Medicare GLP-1 Bridge: $50 per monthly fill (with conditions) | See Medicare guide for details + workarounds[3] |
| Aetna Medicaid | Limited | Depends on your state's Medicaid rules: 13 states (as of January 2026) covered GLP-1s for obesity[4] |
Status key: Excluded = not on formulary Varies = depends on employer Limited = restricted coverage
More Details / Next Steps (Based on Plan Type)
Self-Funded Employer Plans — Your Best Chance
Many large companies pay for healthcare themselves (this is called "self-funded"). Aetna just handles the paperwork.
That means your employer — not Aetna or CVS Caremark — decides whether drugs like Zepbound are covered.
Standard/Advanced Control Plans — Preferred Again Since October 1, 2026
If you have a standard Aetna commercial plan, CVS Caremark's formulary applies. Zepbound was removed effective July 1, 2025 and added back as a preferred option on October 1, 2026; prior authorization applies where your plan covers weight-loss drugs.
- Request a formulary exception (medical necessity)
- Coverage through sleep apnea indication
- Switch to covered alternative (Wegovy)
- Self-pay options
ACA Marketplace Plans — Aetna Left the Marketplace for 2026
Aetna stopped selling ACA marketplace (individual exchange) plans for 2026. If you had an Aetna marketplace plan in 2025, your 2026 marketplace plan is with another insurer, so check that plan's formulary.
- Coverage through sleep apnea or diabetes
- Switching plans during open enrollment
- Self-pay options
Aetna Medicare Advantage — Not by the Plan; Medicare GLP-1 Bridge Instead
Basic Medicare Part D coverage excludes drugs used for weight loss, and that applies to the drug coverage in Aetna's Medicare Advantage plans too. But if your Aetna plan includes drug coverage (MA-PD), you may be able to use the Medicare GLP-1 Bridge, a temporary CMS program that runs outside your Part D benefit. It covers the Zepbound KwikPen only (not vials or single-dose pens) for $50 per monthly fill if you meet CMS's eligibility criteria and your prescriber gets prior authorization.
- Coverage for type 2 diabetes (Mounjaro may be covered)
- Weight loss: the Medicare GLP-1 Bridge (Zepbound KwikPen only, $50 per monthly fill)
- Sleep apnea: Your Part D plan may cover Zepbound for moderate-to-severe sleep apnea, usually with prior authorization (the OSA indication is for adults with obesity (BMI ≥30); people with moderate-to-severe OSA can't use the Bridge)[12]
- Self-pay options: LillyDirect ($299–$449/month; TrumpRx lists the same prices), or Foundayo (oral GLP-1, $149–$299/month)
Medicare GLP-1 Bridge: Live Now
Medicare GLP-1 Bridge: live July 1, 2026 – December 31, 2027, with a $50 per monthly fill copay. Part D plans and pharmacies don’t opt in, and you don’t enroll separately; your prescriber must get prior authorization.
BALANCE Model: CMS announced this voluntary model in December 2025.[13] In Part D it is Delayed, with no new start date.[13]
TrumpRx: Launched February 5, 2026. TrumpRx lists the manufacturers’ own self-pay prices (not a separate, cheaper price); for Zepbound that's the LillyDirect price, open to anyone paying cash, including Medicare beneficiaries.
Update: The exclusion has ended on standard formularies — Zepbound has been a preferred option on standard Aetna formularies since October 1, 2026.
Check the 2026 outlook →FIND YOUR PATHBased on Your Situation
Based on Your Situation
Now that you understand coverage patterns, here's what to do next:
PA Denied?
Your plan covers Zepbound, but your prior authorization was rejected.
- 65%+ overturn rate with proper documentation
- You have 180 days to file an appeal (check your denial letter)
Plan Excludes It?
Zepbound isn't on your formulary (your plan's list of covered drugs) at all.
- Request a formulary exception
- Consider covered alternatives like Wegovy
- Explore self-pay options (LillyDirect $299–$449/month, also listed on TrumpRx; Foundayo $149–$299/month)
Still Checking?
Haven't applied yet or want to understand your options first.
- Use our call script to verify with Aetna
- Check the 2026 outlook for coverage trends
Not Sure Which Applies? Check your denial letter.
- "Not medically necessary" or "step therapy required" = PA denial (you can appeal)
- "Excluded benefit" or "not covered" = plan exclusion (different strategy needed)
WHAT'S COMING
Aetna Coverage Outlook for 2026
Update: Zepbound Returned to Aetna Formularies October 1, 2026
On May 28, 2026, CVS Caremark (Aetna's PBM) announced it would add Zepbound back to its commercial template formularies as an "additional preferred option," effective October 1, 2026 (Wegovy keeps its preferred status).[14] Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize), for plans that cover weight-loss drugs; prior authorization still applies. If your plan uses a customized formulary that still excludes Zepbound, use the exception path below. CVS's announcement didn't spell out formulary tier/copay or sleep apnea; Aetna's published Zepbound criteria define both a weight-loss and a sleep-apnea (OSA) route, but confirm your plan applies them.[15]
What to Watch For
Standard Commercial Plans
The July 2025 exclusion ran through September 30, 2026. Since October 1, 2026, CVS Caremark lists Zepbound as an "additional preferred option" alongside Wegovy on its commercial template formularies.[14]
- Zepbound has been an "additional preferred option" since October 1, 2026 (Wegovy keeps its preferred status)[14]
- Eligible commercial patients: as little as $25/month with the Lilly savings card (excludes Medicare/Medicaid/TRICARE/VA) — this is a manufacturer discount, not your plan copay[11]
- CVS did not specify formulary tier/copay; Aetna's published Zepbound criteria include both weight-loss and OSA routes[15]
- Plans with customized formularies that still exclude Zepbound: exception requests remain the path
Self-Funded Employer Plans
Self-funded employers continue to have flexibility to include or exclude Zepbound based on their own cost analysis.
- Some employers adding GLP-1 coverage due to employee demand
- Others removing coverage due to cost concerns
- Check with HR during open enrollment for 2026 changes
Medicare/Medicaid Policy Changes
The Medicare GLP-1 Bridge is live (July 1, 2026 – December 31, 2027) and covers the Zepbound KwikPen only (not vials or single-dose pens) for $50 per monthly fill for Part D enrollees who meet CMS's criteria and get prior authorization. See our Medicare coverage guide for the latest updates.
- Basic Medicare Part D coverage excludes drugs used for weight loss; the Bridge works outside that exclusion
- BALANCE in Part D: Delayed, with no new start date
- Medicaid coverage remains state-dependent
What This Means for You
- Check your specific plan: Self-funded employers can still choose to cover Zepbound
- During open enrollment: Ask HR about 2026 GLP-1 coverage changes
- Consider alternatives: Wegovy is also a preferred option on standard CVS Caremark formularies
- Self-pay options: LillyDirect ($299–$449/month; TrumpRx lists the same prices), or Foundayo ($149–$299/month oral GLP-1); 2026 savings card caps savings at $100 per 1-month fill for covered patients[11]
CALL YOUR INSURANCEVerify Your Specific Coverage
Verify Your Specific Coverage
Even though it takes a little more time, we recommend calling so you can speak with a person who may have more information than the online directory or PDF formulary listing.
Call Script for Aetna
"Hi, I'm calling to check coverage for a prescription medication. My member ID is [NUMBER]. I need to know:
- Is Zepbound (tirzepatide) currently covered on my plan's formulary for weight management?
- If not, is there an exception process I can request?
- What alternative GLP-1 medications ARE covered on my plan?
- If covered, what tier is it on and what are the prior authorization requirements?
- Can you send me the coverage policy in writing?"
Pro tip: Always request coverage criteria in writing. Verbal confirmations aren't binding, and having documentation helps if you need to appeal later.
Check Your Coverage Online
You can also look up Zepbound coverage on Aetna's website:
- Log in to your Aetna member account
- Go to "Find a Medication" or "Drug Lookup"
- Search for "Zepbound" or "tirzepatide"
- Review your plan's coverage status and any requirements
Have a Self-Funded Employer Plan? Talk to HR
If your employer self-funds their health plan (common at large companies), they—not Aetna—decide what's covered. Here's how to advocate for Zepbound coverage:
- Ask HR: "Does our plan cover GLP-1 medications for weight management? If not, who decides our formulary?"
- Make the business case: Obesity treatment reduces long-term healthcare costs (diabetes, heart disease, joint problems)
- Gather support: If coworkers also want coverage, a group request carries more weight
- Time it right: Ask HR when next year's benefits are decided, and raise the request before then
- Be patient: Formulary changes typically take effect at the next plan year
FOR PLANS THAT COVER ZEPBOUNDPrior Authorization Requirements
Prior Authorization Requirements
Who These Requirements Apply To
Since October 1, 2026, Zepbound is a preferred option again on standard Aetna/CVS Caremark commercial plans, so these prior-authorization requirements apply wherever your plan covers weight-loss drugs. From July 2025 to September 2026, while Zepbound was excluded on most standard plans, they applied mainly to self-funded plans that kept it, exception requests, and the sleep-apnea (OSA) pathway.[7]
Where Zepbound is covered, Aetna's published Zepbound criteria require:[15]
- A 6-month weight-management program first — documented behavioral modification, reduced-calorie diet, and increased physical activity with continuing follow-up
- BMI ≥30, or ≥27 with a weight-related condition (for example hypertension, type 2 diabetes, or dyslipidemia). Some plans use a stricter version (policy 6450-C) that requires BMI ≥35
- Age 18+
- No drug step appears in Aetna's published criteria. Some plans may require trying another drug first; check your plan’s criteria.
Renewal Requirement — Don't Miss This
Under Aetna's published Zepbound criteria,[15] your initial weight-management approval runs 8 months. To renew, you need at least 3 months of therapy at a stable maintenance dose and proof you've lost ≥5% of your starting body weight (or kept off your initial 5%); renewals then run 12 months. There's also a quantity limit (4 pens per 21 days). If you don't meet the weight-loss threshold, your renewal may be denied. (For the sleep-apnea pathway, initial approval runs 6 months and renewals 12 months.)
For complete documentation checklists and PA preparation: Zepbound Prior Authorization Guide →
YOUR PLAN COVERS ITIf Your PA Was Denied
If Your PA Was Denied
Your plan covers Zepbound, but the prior authorization was rejected. This is actually good news — 65%+ of appeals succeed when properly documented.[5]
Why Fight for Coverage?
Win your appeal → pay as little as $25/month with Lilly's 2026 savings card (max $100 per 1-month fill, $1,300 a year (13 fills)).[11] Without coverage, you'd pay $299–$449/month via LillyDirect (TrumpRx lists the same prices). That can mean hundreds of dollars a month in savings — worth the fight.
Common PA Denial Reasons
- Medical necessity not met → Medical Necessity Guide
- Step therapy required → Step Therapy Guide
- BMI criteria not met → BMI Criteria Guide
- Missing lifestyle documentation → Lifestyle Documentation Guide
Aetna Appeal Basics
- Deadline: 180 days from denial to file internal appeal (check your letter)
- Aetna pharmacy services (general questions): 1-888-792-3862; for your plan, call the number on your ID card
- Tip: Ask your doctor for a peer-to-peer review with Aetna's medical director
For complete appeal strategies: Zepbound Appeals Guide → | External Review Process
denied approved
Honest Care helps patients fight back:
Evidence-backed appeal letters — plus personalized guidance to appeal with confidence.
DIFFERENT STRATEGY NEEDEDIf Your Plan Excludes Zepbound
If Your Plan Excludes Zepbound
Zepbound isn't on your plan's drug list at all. Standard appeals won't work for a plan exclusion, but you have other options.
Your Options
- Request a formulary exception — your doctor can argue medical necessity → What to do if Zepbound is not covered
- Consider Wegovy — it's also a preferred GLP-1 on standard CVS Caremark formularies → Compare Alternatives
- Switch plans during open enrollment — if your employer offers multiple options, check for GLP-1 coverage
- Explore self-pay options — LillyDirect ($299–$449/month; TrumpRx lists the same prices), Foundayo ($149–$299/month oral); savings cards and patient assistance may help → Zepbound Cost Guide
What About Sleep Apnea (OSA)?
OSA Coverage During and After the Exclusion
Zepbound became the first FDA-approved medication for obstructive sleep apnea on December 20, 2024.[6] CVS Caremark's 2025 exclusion applied to Zepbound itself, and Aetna's exception policy during that period pointed requests to Wegovy or Mounjaro rather than giving Zepbound its own sleep-apnea route.[2] Aetna's current criteria do include an OSA route: moderate-to-severe OSA (AHI ≥15) and BMI ≥30; 6-month initial approval, 12-month renewal.[15]
If you have sleep apnea and want Zepbound coverage:
- Check whether your plan uses the standard formulary (Zepbound preferred again) or a customized one
- Compare other insurers' sleep-apnea criteria — for example, UHC’s commercial sleep apnea policy (P 1475-3) is Zepbound-only: BMI ≥30 and an AHI, REI or RDI over 15, plus other conditions; 6-month first approval (see our UnitedHealthcare guide)[10]
- Request a formulary exception with sleep study documentation
AETNA ZEPBOUND COVERAGE
Frequently Asked Questions
The picture changed on October 1, 2026. Since that date, CVS Caremark (Aetna's PBM) lists Zepbound on its commercial template formularies as an "additional preferred option," so where your plan covers weight-loss drugs it's covered again with prior authorization. If your plan uses a customized formulary that still excludes Zepbound, your options are: (1) ask your HR department whether your employer plan can add coverage; (2) request a formulary exception with documentation showing why you need Zepbound (for example, another drug didn't work or you have contraindications); (3) if denied, appeal—over 65% of appeals succeed with proper documentation. CVS's announcement did not say whether the sleep-apnea (OSA) indication is included, so confirm specifics by calling the number on your Aetna card.
On standard plans, yes again. From July 1, 2025 through September 30, 2026, Zepbound was nonpreferred or excluded on CVS Caremark's most common commercial template formularies (not every plan), and standard Aetna formularies listed it as non-formulary. Since October 1, 2026, CVS Caremark (Aetna's PBM) lists Zepbound on its commercial template formularies as an "additional preferred option," so where your plan covers weight-loss drugs it's covered again with prior authorization. Customized employer formularies may differ, so check with HR. Wegovy remained a preferred option throughout.
CVS Health owns Aetna, and CVS Caremark manages Aetna's pharmacy benefits. When CVS Caremark made Zepbound nonpreferred or excluded on its most common commercial template formularies in July 2025, standard Aetna formularies followed suit. CVS Caremark said it partnered with Novo Nordisk (Wegovy's manufacturer) to offer Wegovy at a more affordable price, making Wegovy the preferred GLP-1 medication. On October 1, 2026, CVS Caremark added Zepbound back to its commercial template formularies as an additional preferred option. Zepbound has a list price of about $1,086/month (see our cost guide for savings options). For more details on this change, see our CVS Caremark coverage guide.
Yes, exception requests are possible but not easy to win. You'll need strong medical documentation showing: (1) you tried Wegovy or other covered medications but they didn't work for you, or (2) you have medical reasons why you can't take the alternatives, or (3) you're requesting coverage for sleep apnea rather than weight loss. Work with your doctor to put together a strong case with supporting evidence.
For plans that cover Zepbound, Aetna's published criteria require: BMI of 30 or higher, or BMI of 27+ with a weight-related condition like high blood pressure, type 2 diabetes or high cholesterol (some plans use a stricter version that requires BMI 35+), age 18+, and 6 months in a documented weight-management program (diet, exercise and behavior changes). No drug step appears in Aetna's published criteria, but some plans may require trying another drug first; check your plan’s criteria. Always ask for your plan's specific criteria in writing.
For employer and ACA-regulated plans you have 180 days to file an internal appeal with Aetna (your denial letter states your exact deadline). Start by requesting the denial letter so you know exactly why they said no. Then submit an appeal with: a letter from your doctor explaining why you need Zepbound, documentation showing other medications didn't work for you, and research evidence supporting Zepbound. If Aetna still says no, you can request an external review within 4 months (check your state)—an independent organization reviews your case. If the reviewer overturns the denial, Aetna must cover the medication.
Possibly, since October 1, 2026. From July 2025 to September 2026, Zepbound was excluded on standard Aetna (CVS Caremark) formularies for BOTH weight loss AND sleep apnea (OSA) indications, on the rationale that Zepbound's OSA benefits come through weight loss. Since October 1, 2026, CVS Caremark lists Zepbound on its commercial template formularies as a preferred option again. Aetna's published Zepbound criteria do define an OSA route — a BMI ≥30 plus a moderate-to-severe OSA diagnosis (AHI ≥15 events/hour on a sleep study) — so the coverage criteria exist; what the reversal announcement didn't separately confirm is whether your specific plan applies the OSA indication, so verify before relying on it. A self-funded employer plan may also have kept OSA coverage. In Medicare, Zepbound may be covered under Part D for moderate-to-severe OSA in adults with obesity (BMI ≥30), subject to the plan's formulary, prior authorization and exceptions process—through the Part D plan, not the GLP-1 Bridge, and separate from Aetna commercial coverage. Other insurers set their own OSA criteria; for example, UHC’s commercial sleep apnea policy (P 1475-3) is Zepbound-only: BMI ≥30 and an AHI, REI or RDI over 15, plus other conditions; 6-month first approval. See our complete OSA coverage guide.
YOUR PATH FORWARD
What's Next
Zepbound Coverage: Other Major Insurers
See how other insurers compare on Zepbound coverage:
- UnitedHealthcare — Depends on your employer’s plan; PA required where covered
- Blue Cross Blue Shield — Varies by Blue company; some (e.g., Massachusetts) dropped weight-loss coverage in 2026
- Cigna — Depends on your employer's plan; PA required (Cigna policy IP0816)
- Anthem Blue Cross — Separate policies from other BCBS affiliates
- Kaiser Permanente — Depends on your region and plan
Other GLP-1 Medications at Aetna
Aetna's coverage varies by medication. Compare your options:
References
- CVS Health. (June 27, 2025). "Improving access and affordability to high-cost weight management drugs." https://www.cvshealth.com/news/pbm/improving-access-and-affordability-to-high-cost-weight-management-drugs
- Aetna. (July 1, 2025). "Zepbound Exception, Policy 6981-A" (Primary formulary alternative: Wegovy; secondary: Mounjaro). aetna.com
- Centers for Medicare & Medicaid Services. (2024). "Medicare Prescription Drug Benefit Manual, Chapter 6." Part D exclusions. https://www.cms.gov/medicare/prescription-drug-coverage/prescriptiondrugcovcontra/partdmanuals
- KFF. "Medicaid Coverage of and Spending on GLP-1s." https://www.kff.org/medicaid/issue-brief/medicaid-coverage-of-and-spending-on-glp-1s/
- American Medical Association / KFF Analysis. (2024). "Over 80% of Prior Auth Appeals Succeed—Why Aren't There More?" https://www.ama-assn.org/practice-management/prior-authorization/over-80-prior-auth-appeals-succeed-why-aren-t-there-more
- FDA. (2024). "FDA Approves First Medication for Obstructive Sleep Apnea." https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
- Eli Lilly. (2025). "Zepbound Prior Authorization Resource Guide." https://zepbound.lilly.com/assets/pdf/zepbound_Prior_Authorization_Resource_Guide.pdf
- Honest Care. (2025). "GLP-1 Patient Access Report — Q3/Q4 2025." https://www.findhonestcare.com/insights/glp1-coverage-2025/
- Mass.gov. (2025). "CVS Caremark decides to remove Zepbound from CVS Caremark formulary." https://www.mass.gov/news/cvs-caremark-decides-to-remove-zepbound-from-cvs-caremark-formulary
- UnitedHealthcare. (2026). "Zepbound (tirzepatide) – Obstructive Sleep Apnea Only" (2026 P 1475-3). https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Non-Formulary-Zepbound.pdf
- Eli Lilly and Company. "Zepbound Savings Card terms." https://zepbound.lilly.com/savings
- CMS. "Medicare GLP-1 Bridge: Information for Part D Plans." https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
- CMS. (2025). "CMS Launches Voluntary Model to Expand Access to Life-Changing Medicines." BALANCE model announcement. https://www.cms.gov/newsroom/press-releases/cms-launches-voluntary-model-expand-access-life-changing-medicines-promote-healthier-living
- CVS Health. (2026). "CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications with Expanded Coverage Options." Announced May 28, 2026: Zepbound returns to standard commercial formularies as an additional preferred option effective October 1, 2026. https://www.cvshealth.com/news/company-news/cvs-caremark-delivers-affordability-and-access-to-glp-1-weight-management-medications-with-expanded-coverage-options.html
- Aetna / CVS Caremark. Zepbound prior-authorization criteria: policy 6947-C (BMI 30 version, July 2025) and policy 6450-C (BMI 35 version, April 2026). Weight loss: 8-month initial, 12-month renewal; OSA: 6-month initial, 12-month renewal; quantity limit 4 pens per 21 days. 6947-C (aetna.com); 6450-C (aetna.com)
Last updated October 6, 2026 · Key facts verified October 5, 2026 · Full page reviewed October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.